View Bravecto 1-Month Drug Facts Sheet.
Bravecto 1-Month should be administered orally as a single dose monthly according to the Dosage Schedule below to provide a minimum dose of 4.5 mg/lb (10 mg/kg) fluralaner.
Bravecto 1-Month should be administered with food.
| Body Weight Ranges (lb) |
Fluralaner Content (mg) |
Chews Administered |
| 4.4-9.9 |
45 |
One (Yellow) |
| >9.9-22.0 |
100 |
One (Orange) |
| >22.0-44.0 |
200 |
One (Green) |
| >44.0-88.0 |
400 |
One (Blue) |
| Dogs over 123.0 lb should be administered the appropriate combination of chews |
Treatment with Bravecto 1-Month may begin at any time of the year and can continue year-round without interruption.
Caution:
Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
Contraindications:
There are no known contraindications for the use of the product.
Warnings:
Not for human use. Keep this and all drugs out of the reach of children. Keep the product in the original packaging until use, in order to prevent children from getting direct access to the product. Do not eat, drink or smoke while handling the product. Wash hands thoroughly with soap and water immediately after use of the product.
Keep Bravecto 1-Month in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose.
Precautions:
Fluralaner is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures. Seizures have been reported in dogs receiving isoxazoline class drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders.
Bravecto 1-Month is not effective against A. americanum in puppies less than 6 months of age (see Effectiveness).
The safety of Bravecto 1-Month has not been evaluated in breeding, pregnant and lactating dogs (see Animal Safety).
Effectiveness:
Treatment and Prevention of Flea Infestations:
- In well-controlled laboratory studies in dogs 6 months of age and older, Bravecto 1-Month started killing fleas within 4 hours after treatment and was > 99% effective by 12 hours after treatment or post-infestation for 35 days.
- In a well-controlled laboratory study in dogs 8 weeks of age and older, Bravecto 1-Month demonstrated 100% effectiveness against fleas for 30 days.
- In a well-controlled 90-day U.S. field study conducted in households with existing flea infestations, the effectiveness of Bravecto 1-Month against fleas on Day 30, 60, and 90 visits compared with baseline was 99.6%, 99.9%, and 99.9%, respectively. Dogs with signs of flea allergy dermatitis showed improvement in erythema, alopecia, papules, scales, crusts, and excoriation as a direct result of eliminating flea infestations.
Treatment and Control of Tick Infestations:
- In well-controlled laboratory studies in dogs 8 weeks of age and older, Bravecto 1-Month demonstrated ?97.7% effectiveness against Rhipicephalus sanguineus ticks at 48 hours after treatment or infestation for 30 days.
- In well-controlled laboratory studies, fluralaner, the active ingredient in Bravecto 1-Month, demonstrated effectiveness against Ixodes scapularis and Dermacentor variabilis.
- In well-controlled laboratory studies in dogs 6 months of age and older, Bravecto 1-Month demonstrated >96% effectiveness against Amblyomma americanum at 48- and 72-hours after treatment or infestation for 31 days.
- Bravecto 1-Month failed to demonstrate >90% effectiveness against Amblyomma americanum in 8-week-old puppies.
Palatability:
In a well-controlled U.S. field study, which included 579 doses administered to 201 dogs, 81.5% of dogs voluntarily consumed Bravecto 1-Month within 5 minutes, an additional 9.0% voluntarily consumed Bravecto 1-Month within 5 minutes when offered with food, and 9.5% required forced administration.
Animal Safety:
Margin of Safety Study:
In a margin of safety study, Bravecto 1-Month was administered orally to 8-week old puppies at 1, 3, and 5× the maximum labeled dose of 22.5 mg/kg with 8 dogs per group at three, 30-day intervals (Days 1, 31 and 61). The dogs in the control group were untreated.
There were no clinically-relevant, treatment-related effects on body weights, food consumption, organ weights, hematology, C-reactive protein, coagulation profile, urinalysis, gross pathology and histopathology. Diarrhea and mucoid or discolored feces were the most common observations, occurring at a similar incidence in the treated and control groups. Vomiting was noted in one dog in the 5× group and one dog in the control group on Day 2. Splayed hind limbs were noted in one dog in the 1× treatment group post-dose on Day 61. Tremors were noted in one dog in each of the 3 fluralaner dose groups on Day 1 at 4 hours post-dose. Trembling was noted in one dog in the 1× group on Day 2. Blood urea nitrogen (BUN) was elevated in one dog in the 3× group on Day 8. BUN and serum creatinine were elevated in one dog in the 5× group on Day 85.
Reproductive Safety Study:
Reproductive safety was evaluated for fluralaner, the active ingredient in BRAVECTO 1-Month. Fluralaner was administered orally to intact, reproductively-sound male and female Beagles at a dose of up to 168 mg/kg on three to four occasions at 8-week intervals. The dogs in the control group were untreated. There were no clinically-relevant, treatment-related effects on the body weights, food consumption, reproductive performance, semen analysis, litter data, gross necropsy (adult dogs) or histopathology findings (adult dogs and puppies). One adult dog in the treated group suffered a seizure during the course of the study (46 days after the third treatment). Abnormal salivation was observed on 17 occasions: in six treated dogs (11 occasions) after dosing and four control dogs (6 occasions).
The following abnormalities were noted in 7 pups from 2 of the 10 dams in only the treated group during gross necropsy examination: limb deformity (4 pups), enlarged heart (2 pups), enlarged spleen (3 pups), and cleft palate (2 pups). During veterinary examination at Week 7, two pups from the control group had inguinal testicles, and two and four pups from the treated group had inguinal and cryptorchid testicles, respectively. No undescended testicles were observed at the time of necropsy (days 50 to 71).
In a well-controlled field study
Bravecto 1-Month was used concurrently with other medications, such as vaccines, anthelmintics, antibiotics (including topicals), steroids, analgesics, and anesthetics. No adverse reactions were observed from the concurrent use of Bravecto 1-Month with other medications.
Storage:
Do not store above 86°F (30°C).
